GOCOVRI

Peak

amantadine

NDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7

Mechanism of Action

M2 Protein Inhibitors

Pharmacologic Class:

Influenza A M2 Protein Inhibitor

Clinical Trials (5)

NCT01227967Phase 2Completed

Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

Started Sep 2010
NCT00975611Phase 4Terminated

Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation

Started Oct 2009
6 enrolled
SchizophreniaSchizoaffective Disorder
NCT00416962Phase 1Completed

Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine

Started Aug 2006
18 enrolled
Healthy
NCT00287352Phase 1Completed

Study of Amantadine for Weight Stabilization During Olanzapine Treatment

Started May 2005
40 enrolled
Psychotic DisorderSchizophreniform DisorderSchizophrenia+2 more
NCT00199719Phase 2Completed

Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM

Started Jun 2003
30 enrolled
Chronic Hepatitis C

Loss of Exclusivity

LOE Date
Aug 23, 2038
151 months away
Patent Expiry
Aug 23, 2038

Patent Records (5)

Patent #ExpiryTypeUse Code
8389578
Jan 22, 2028
U-2105
9877933
Dec 2, 2030
U-2224
9867793
Dec 2, 2030
U-2106
11197835
Dec 2, 2030
U-2106
8741343
Dec 2, 2030
U-2106